Metabolic & Cardiometabolic · Gut & Microbiome
oral bile acid (CDCA) increases GLP-1
In plain terms: Does an oral bile acid boost the gut hormone GLP-1 in people?
Probably yes for the bile acid itself, but whether ordinary diet can do the same is unproven.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
Direct chenodeoxycholic acid raises GLP-1 in humans (intragastric, and post-RYGB), but bile-acid SEQUESTRANTS do not raise GLP-1 in humans despite lowering glucose — so the human glucose benefit of sequestrants is not GLP-1-mediated. Bile acids CAN drive human GLP-1; whether diet can is unproven.
The evidence (17)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kuhre RE, Wewer Albrechtsen NJ, Larsen O, Jepsen SL, Balk-Møller E, Andersen DB, Deacon CF, Schoonjans K, Reimann F, Gribble FM, Albrechtsen R, Hartmann B, Rosenkilde MM, Holst JJ 2018 · Mol Metab | animal | supports | moderate | Bile acids are direct and indirect regulators of GLP-1 and other gut/pancreatic hormone secretion. |
| Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law JH, Cobelli C, Zinsmeister AR, Rizza RA, Vella A 2013 · (human RCT) | RCT | tested-null | moderate | n=38 RCT 12wk: improved glycemia but postprandial GLP-1 UNCHANGED (mechanism = glucose sequestration) |
| Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T, Hellerstein MK 2012 · Diabetologia | RCT | supports | moderate | Colesevelam improved glucose metabolism with bile-acid-mediated GLP-1 mechanism in type-2 diabetes RCT. |
| Sun YH, Ding PL, Wang X, Wang YR, Zhu MZ, Wang K, Dai L, Dang YQ, Ji G, Li M, Zhou WJ 2026 · Pharmaceuticals (Basel, Switzerland) | animal | mixed | low | Mouse MASLD model: herbal decoction (LGZG) enriched endogenous non-12-OH bile acids (HCA, 7-ketoLCA), known TGR5 agonists; serum GLP-1 elevated (p<0.05) alongside adipose TGR5-cAMP/PKA/CREB activation. |
| Christiansen CB, Trammell SAJ, Wewer Albrechtsen NJ, Schoonjans K, Albrechtsen R, Gillum MP, Kuhre RE, Holst JJ 2019 · Am J Physiol Gastrointest | animal | supports | moderate | Bile acids drive colonic GLP-1 and PYY secretion 3.5x via basolateral TGR5 in perfused rat/mouse colon. |
| Roberts RE, Glicksman C, Alaghband-Zadeh J, Sherwood RA, Akuji N, le Roux CW 2011 · Clin Endocrinol | observational | supports | moderate | Postprandial bile acid concentrations correlate with GLP-1 and PYY secretion in humans. |
| Murakami M, Une N, Nishizawa M, Suzuki S, Ito H, Horiuchi T 2013 · SpringerPlus | observational | supports | low | Oral ursodeoxycholic acid with a meal raised GLP-1 secretion and lowered blood glucose in non-diabetic humans. |
| Lv J, Zhou L, Dai X, Landberg R, Meng H, Tian H, Zhang S, Liu T, Yin X, Zhang J, Song X, Bonny C, Blum S, Cao Y, Guo J, Peng W, Tan Y, Shi L 2026 · Gut microbes | animal | tested-null | moderate | Mouse: oral UDCA recapitulated anti-obesity/metabolic benefits of BSH-probiotic; UDCA acted as intestinal FXR antagonist + TGR5 agonist, stimulated GLP-1 secretion; HepG2 cells showed UDCA directly activates GLP-1 receptor. |
| Nielsen S, Svane MS, Kuhre RE, Clausen TR, Kristiansen VB, Rehfeld JF, Holst JJ, Madsbad S, Bojsen-Moller KN 2017 · (human crossover) | RCT | supports | moderate | Oral CDCA raised GLP-1/PYY/FGF19 in post-RYGB (n=11); UDCA did not |
| Brønden A, Albér A, Rohde U, Gasbjerg LS, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK 2018 · Diabetes Obes Metab | RCT | mixed | high | Sevelamer (bile-acid sequestrant) abolished the acute endogenous-bile-acid GLP-1 stimulus in T2D-confirms bile acids drive GLP-1. |
| Hansen M, Scheltema MJ, Sonne DP, Hansen JS, Sperling M, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK 2016 · (human crossover) | RCT | supports | moderate | Intragastric CDCA increased plasma GLP-1 (human crossover) |
| Wu T, Bound MJ, Standfield SD, Gedulin B, Jones KL, Horowitz M, Rayner CK 2013 · Diabetes Obes Metab | RCT | supports | moderate | Rectal taurocholic acid dose-dependently stimulated GLP-1 and PYY in healthy men. |
| Ma H, Wu Y, Li D, Sun H, Xie Y, Zhao S, Guo W, Wang M, Cui R, Huang Y, Zhang X, Wan JY, Yao H, Yuan CS 2026 · Acta pharmaceutica Sinica. B | animal | mixed | moderate | 46 obesity-prone humans had depleted GDCA (observational only, no GLP-1 measured in humans); FMT-recipient + GDCA-supplemented mice: GDCA activated TGR5, increased ileal GLP-1 secretion and BAT thermogenesis. |
| Gether IM, Bahne E, Nerild HH, Rehfeld JF, Hartmann B, Holst JJ, Vilsbøll T, Sonne DP, Knop FK 2024 · (human crossover) | RCT | tested-null | moderate | Single-dose colesevelam: no acute postprandial GLP-1 rise |
| She J, Tuerhongjiang G, Guo M, Liu J, Hao X, Guo L, Liu N, Xi W, Zheng T, Du B, Lou B, Gao X, Yuan X, Yu Y, Zhang Y, Gao F, Zhuo X, Xiong Y, Zhang X, Yu J, Yuan Z, Wu Y 2024 · Cell Metab | mechanism | mixed | high | Statin-driven bile-acid/microbiome shifts reduce GLP-1 and worsen insulin resistance-supports bile-acid-GLP-1 axis indirectly. |
| Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, Gribble FM, Reimann F 2015 · Endocrinology | mechanism | supports | moderate | Bile acids trigger GLP-1 release predominantly via basolateral GPBAR1/TGR5 on L-cells. |
| Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, Briand O, Dehondt H, Vallez E, Dorchies E, Baud G, Spinelli V, Hennuyer N, Caron S, Bantubungi K, Caiazzo R, Reimann F, Marchetti P, Lefebvre P, Bäckhed F, Gribble FM, Schoonjans K, Pattou F, Tailleux A, Staels B, Lestavel S 2015 · Nat Commun | in-vitro | contradicts | moderate | FXR activation (a bile-acid receptor) INHIBITS GLP-1 production by L-cells-bile-acid effect on GLP-1 is receptor-dependent and bidirectional. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.